This article needs additional citations for verification. (September 2018) |
Clinical data | |
---|---|
Trade names | Fanapt, Zomaril |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609026 |
License data |
|
Routes of administration | Oral, injection |
Drug class | Atypical antipsychotic |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 96% (oral; Tmax = 2–4 hours) |
Protein binding | ~97% |
Metabolism | Hepatic (CYP2D6-mediated hydroxylation and CYP3A4-mediated O-demethylation) |
Elimination half-life | 18–33 hours |
Excretion | urine (45.1–58.2%) and feces (19.9–22.1%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.106.441 |
Chemical and physical data | |
Formula | C24H27FN2O4 |
Molar mass | 426.488 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Iloperidone, commonly known as Fanapt and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia and bipolar I disorder.